MetaCap

Tempest Therapeutics Inc. Company Profile

NASDAQ: TPSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.287-0.0189 (-6.18%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Tempest Therapeutics at a glance

Tempest Therapeutics Inc. (NASDAQ: TPST) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Brisbane, CA. Tempest Therapeutics is led by Dr. Matthew Angel Ph.D. and employs about 4 people. At a market capitalization of $5.7 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001544227, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Tempest Therapeutics do?

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Business description based on the company's public filings.

Company information

Legal name
Tempest Therapeutics Inc.
Ticker
NASDAQ: TPST
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Matthew Angel Ph.D.
Employees
4
Headquarters
2000 Sierra Point Parkway, Brisbane, CA, United States
Phone
415 798 8589
SEC CIK
0001544227
Latest annual report
10-K · Mar 30, 2026

Companies similar to Tempest Therapeutics

TPST peer companies
CompanyPrice% ChgMarket capCompare
LGVNLongeveron Inc. Class A1.66-8.79%$5.60Mvs TPST
XCURExicure Inc.0.9001-12.82%$5.89Mvs TPST
TOVXTheriva Biologics Inc.0.12-6.25%$5.51Mvs TPST
ENVBEnveric Biosciences Inc.1.35-4.26%$6.04Mvs TPST
UPCUniverse Pharmaceuticals Inc. Class A1.08-20.59%$5.43Mvs TPST
ADXNAddex Therapeutics Ltd ADR3.47+2.06%$6.08Mvs TPST
CNSPCNS Pharmaceuticals Inc.3.56-12.75%$5.25Mvs TPST
ACXPAcurx Pharmaceuticals Inc.1.04+0.97%$6.30Mvs TPST

Related